Vivos Therapeutics, Inc. (NASDAQ:VVOS) Short Interest Up 28.9% in December

Vivos Therapeutics, Inc. (NASDAQ:VVOS) saw a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 148,000 shares, a growth of 28.9% from the November 30th total of 114,800 shares. Based on an average trading volume of 207,100 shares, the days-to-cover ratio is currently 0.7 days. Approximately 3.9% of the shares of the company are sold short.

Analysts Set New Price Targets

VVOS has been the topic of a number of research reports. Alliance Global Partners cut their target price on shares of Vivos Therapeutics from $8.25 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, November 19th. Ascendiant Capital Markets restated a “buy” rating and issued a $6.60 price objective on shares of Vivos Therapeutics in a report on Wednesday, November 20th.

Vivos Therapeutics Stock Down 3.2 %

Shares of Vivos Therapeutics stock opened at $4.50 on Monday. Vivos Therapeutics has a 12 month low of $1.91 and a 12 month high of $12.75. The business has a fifty day simple moving average of $3.57 and a 200 day simple moving average of $2.90. The stock has a market cap of $21.76 million, a PE ratio of -0.79 and a beta of 7.67.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.